Leick Mark, Gittelman Rachel M, Yusko Erik, Sanders Catherine, Robins Harlan, DeFilipp Zachariah, Nikiforow Sarah, Ritz Jerome, Chen Yi-Bin
Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
Adaptive Biotechnologies, Seattle, Washington.
Biol Blood Marrow Transplant. 2020 Sep;26(9):1567-1574. doi: 10.1016/j.bbmt.2020.04.026. Epub 2020 May 15.
Delayed reconstitution of the immune system is a long-recognized complication after allogeneic hematopoietic cell transplantation (HCT). Specifically, loss of T cell diversity has been thought to contribute to infectious complications, graft-versus-host disease (GVHD), and disease relapse. We performed serial high-resolution next-generation sequencing of T cell receptor (TCR)-β in 99 related or unrelated donor (57 unrelated, 42 related) allogeneic HCT recipients (55 with reduced-intensity conditioning, 44 with myeloablative conditioning) during the first 3 months after HCT using the immunoSEQ Assay. We measured T cell fraction, clonality (1- Peilou's evenness) and Daley-Smith richness from recipient samples at multiple time points. In agreement with previous studies, we found that although absolute T cell numbers recover relatively quickly after HCT, T cell repertoire diversity remains diminished. Restricted diversity was associated with conditioning intensity, use of antithymocyte globulin, and donor type. Increased number of expanded clones compared to donor T cell clones at day +30 was associated with the incidence of acute GVHD (hazard ratio [HR], 1.11; P = .00005). Even after exclusion of the 12 patients who developed acute GVHD before day +30, the association between acute GVHD and increased clonal expansion at day +30 remained (HR, 1.098; P = .041), indicating that increased clonal T cell expansion preceded the development of acute GVHD. Our results highlight T cell clonal expansion as a potential novel biomarker for acute GVHD that warrants further study.
免疫系统重建延迟是异基因造血细胞移植(HCT)后长期公认的并发症。具体而言,T细胞多样性的丧失被认为会导致感染性并发症、移植物抗宿主病(GVHD)和疾病复发。我们使用免疫SEQ检测法,对99例相关或无关供体(57例无关供体,42例相关供体)的异基因HCT受者(55例接受减低强度预处理,44例接受清髓性预处理)在HCT后的前3个月进行了T细胞受体(TCR)-β的系列高分辨率下一代测序。我们在多个时间点测量了受者样本中的T细胞分数、克隆性(1 - 皮尔洛均匀度)和戴利 - 史密斯丰富度。与先前的研究一致,我们发现尽管HCT后绝对T细胞数量相对较快恢复,但T细胞库多样性仍然减少。受限的多样性与预处理强度、抗胸腺细胞球蛋白的使用和供体类型有关。与供体T细胞克隆相比,在第30天扩增克隆数量增加与急性GVHD的发生率相关(风险比[HR],1.11;P = 0.00005)。即使排除了在第30天之前发生急性GVHD的12例患者,急性GVHD与第30天克隆扩增增加之间的关联仍然存在(HR,1.098;P = 0.041),这表明克隆性T细胞扩增增加先于急性GVHD的发生。我们的结果突出了T细胞克隆扩增作为急性GVHD潜在的新型生物标志物,值得进一步研究。